Novo Nordisk Logo
Gradual Addition of NovoLog® at Mealtime Can Reduce A1c in Type 2 Diabetes Patients
Novo Nordisk announced results of its STEPwise™ trial, which identified a method of intensifying insulin treatment with NovoLog® (insulin aspart [rDNA origin] injection). The study, presented at the American Diabetes Association (ADA) 2010 Scientific Sessions, demonstrated a reduction of A1c levels in type 2 diabetes patients when a dose of NovoLog® was introduced at meals, using two approaches that start with the largest meal of...
depomed_logo
Type 2 Diabetics May be Able to Tolerate Higher Doses of Metformin Using Glumetza
A press release issued today by Depomed, Inc. and Santarus, Inc says that according to the clinical trial results, patients previously intolerant of metformin may be able to tolerate higher efficacious doses of metformin when treated with GLUMETZA, with fewer gastrointestinal side effects. GLUMETZA is a once-daily, extended release formulation of metformin, and is approved for use in adults with type 2 diabetes...
Amylin Lilly Logo
Byetta Helps Type 2 Diabetics Achieve Blood Glucose Control
Amylin Pharmaceuticals, Inc. and Eli Lilly and Company announced results from the first double-blind, placebo-controlled clinical study to evaluate BYETTA(R) (exenatide) injection added to Lantus(R) (insulin glargine), which showed patients with type 2 diabetes achieved glucose targets without weight gain or increasing...
amylin logo
Symlin Does Not Increase Risk of Cardiovascular Event, New Study Shows
Amylin Pharmaceuticals, Inc. announced results from an analysis of an integrated database of clinical studies that showed no increased risk of cardiovascular (CV) events associated with SYMLIN(R) (pramlintide acetate) injection use compared to a pooled comparator group treated with either placebo or rapid-acting insulin...
Novo Nordisk Logo
Victoza Superior to Januvia, New Study Shows
Late-breaking Novo Nordisk extension data presented at the 70th Annual Scientific Sessions of the American Diabetes Association (ADA) showed that once-daily Victoza in combination with metformin produced sustained and significantly greater reductions in A1c, body weight and fasting plasma glucose (FPG) than Januvia plus metformin at 52 weeks...
En Route to Orlando, Florida!
As I write this, I am on a plane to Orlando. Orlando, Florida! Yes, I know it will be humid. And, not, I’m not going to Disney World. But I’m…
Novo Nordisk Logo
Novo Nordisk Presents Positive Phase 2 Data for Ultra-Long-Acting Insulin Degludec
According to a Novo Nordisk press release the company presented phase 2 proof-of-concept data for its investigational insulin degludec, an ultra-long-acting basal insulin, which demonstrated the potential to help achieve target glycemic control when used once daily or three times weekly. These data were presented at the 70th Scientific Sessions of the American Diabetes Association (ADA) in Orlando FL...